Production scientifique

Articles scientifiques

Explorez les publications du département, filtrez par type, année ou mot-clé et accédez rapidement au DOI, au PDF et à la fiche détaillée.

7 publication(s)
Réinitialiser
Page 1 / 1
Article original2026

Genomic surveillance of Mpox virus in the Democratic Republic of the Congo, 2024-2026

Patrick Kabongo Mutombo, Gédéon Kalala Tshimanga, Hypolite Muhindo Mavoko, Kabongo Mutombo P, Kalala Tshimanga G, Hypo Mavoko JP

Whole-genome sequencing of 248 Mpox virus isolates from 14 provinces in DRC reveals substantial genetic diversity and identifies novel clades with potential implications for vaccine efficacy.

Communication courte2026

Sentinel surveillance network for arboviruses in Central Africa: design and preliminary results

Aimée Kahindo Kiyonga, Patrick Kabongo Mutombo, Francis Kasongo Mumba, Ngoie Banza A, Kabongo Mutombo P, Kasongo Mumba F

Description of the design and first-year results of the ARBO-SENTINEL network, a multi-country sentinel surveillance system for dengue, chikungunya, yellow fever and Zika viruses in Central Africa.

Méta-analyse2026

Molecular markers of antimalarial drug resistance in Plasmodium falciparum isolates from Central Africa: a systematic review and meta-analysis

Gédéon Kalala Tshimanga, Sterling Ilunga Kabongo, Béatrice Mwamba Kalala, Kalala Tshimanga G, Ilunga Kabongo S, Mwamba Kalala B

A systematic review and meta-analysis of 87 studies reporting molecular markers of antimalarial drug resistance in P. falciparum from Central Africa, revealing emerging artemisinin partial resistance in western DRC.

Cas clinique2026

A severe case of Monkeypox with visceral involvement in an immunocompromised patient in Kinshasa

Gracia Tshibangu Lukusa, Marie-Claire Mukendi Ngoy, Espoir Bokamba Okito, Tshibangu Lukusa G, Mukendi Ngoy MC, Bokamba Okito E

Case report describing a severe Mpox infection with multi-organ involvement in an HIV-positive patient in Kinshasa, highlighting the need for enhanced clinical management protocols in endemic areas.

Article original2026

Efficacy of the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen in a phase III trial in the DRC

Hypolite Muhindo Mavoko, Patrick Kabongo Mutombo, Marie-Claire Mukendi Ngoy, Hypo Mavoko JP, Kabongo Mutombo P, Mukendi Ngoy MC

A randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen among healthcare workers and at-risk populations in the Democratic Republic of the Congo.

Article original2026

Fexinidazole versus NECT for stage 2 Trypanosoma brucei gambiense human African trypanosomiasis: a multicentre, randomised, phase III trial

Marie-Claire Mukendi Ngoy, Gracia Tshibangu Lukusa, Mukendi Ngoy MC, Tshibangu Lukusa G

This multicentre randomised phase III trial demonstrates non-inferiority of oral fexinidazole compared to the standard NECT regimen for stage 2 HAT, with a cure rate of 95.2% vs 93.8% at 18 months.